mGluR

Metabotropic glutamate receptors (mGluRs) are class C G protein-coupled receptors that bind glutamate and regulate synaptic transmission, neuronal excitability, and activity-dependent plasticity throughout the central nervous system^[1][2]. Mechanistically, mGluRs transduce extracellular glutamate signals through intracellular signaling pathways that modulate ion channels, second messengers, and downstream neuronal responses, thereby influencing learning, memory, and network function^[1][3]. The mGluR family comprises eight receptor subtypes organized into three groups based on sequence homology, pharmacology, and G-protein coupling properties^[2][4]. Group I receptors (mGluR1 and mGluR5) primarily activate phospholipase C-dependent signaling and are predominantly localized postsynaptically, whereas Group II (mGluR2/3) and Group III (mGluR4/6/7/8) receptors generally inhibit cyclic AMP signaling and are frequently associated with presynaptic modulation of neurotransmitter release^[2][4]. Dysregulation of mGluR signaling has been implicated in multiple neurological and neuropsychiatric disorders, including schizophrenia, Parkinson’s disease, epilepsy, anxiety disorders, and neurodegenerative conditions, making these receptors important experimental and therapeutic targets^[1][5]. Compared with related glutamate receptor families, mGluRs mediate slower but longer-lasting modulatory effects through metabotropic signaling rather than direct ion channel gating, providing distinct control over neuronal circuit activity^[3][4]. For experimental applications, subtype-selective agonists, antagonists, and allosteric modulators have become essential tools for dissecting receptor-specific functions, with particularly extensive pharmacological development focused on mGluR5 because of its central role in higher-order brain functions and disease-relevant signaling pathways^[5][6].